"Medizinische Klinik und Poliklinik III LMU - Klinikum der Universität München"
Welcome,         Profile    Billing    Logout  
 13 Trials 
12 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Heinemann, Volker
NCT00440167: Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Checkmark Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
Checkmark Intratumoral Bacterial Lipopolysaccharide (LPS) Detection as Negative Predictor of Gemcitabine Efficacy in Advanced Pancreatic Cancer: Translational Results from the AIO-PK0104 Phase 3 Study
Checkmark In pts with adv pancreatic cancer
Aug 2014 - Aug 2014: In pts with adv pancreatic cancer
Checkmark ASCO-GI 2013
More
Unknown status
3
280
NA
Gemcitabine, Capecitabine, Erlotinib
PD Dr. med. Volker Heinemann, Roche Pharma AG
Pancreatic Cancer
12/11
12/12
FIRE-3, NCT00433927: 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Checkmark Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Checkmark BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI.
Checkmark FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Checkmark [VIRTUAL] Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study
Checkmark Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
More
Unknown status
3
568
Europe
5-FU, folinic acid, irinotecan, cetuximab, bevacizumab
PD Dr. med. Volker Heinemann, Merck KGaA, Darmstadt, Germany
Neoplasm Metastasis, Colorectal Cancer
04/14
12/16
FIRE-4, NCT02934529 / 2014-003787-21: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Checkmark Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (…
Recruiting
3
550
Europe
Irinotecan, Campto, Folinic Acid, Folgamma mono, 5-FU, Fluorouracil, Cetuximab, Erbitux, Bevacizumab, Avastin, Capecitabine, Xeloda, regorafenib, CAS #:755037-03-7, Irinotecan 125mg, Cetuximab wkly
Ludwig-Maximilians - University of Munich
Metastatic Colorectal Cancer
12/22
12/24
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Checkmark [VIRTUAL] RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).
Checkmark [VIRTUAL] Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO
Checkmark A Phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).
Recruiting
3
426
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
12/23
06/24
NCT02912559: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Checkmark Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).
Checkmark Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
Recruiting
3
700
Europe, US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7
04/24
04/24
FOOTPATH, NCT03487016: First-line Therapy in Metastatic PDAC

Recruiting
2
270
Europe
Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, 5-FU, 5-Fluoruracil, Irinotecan Liposomal Injection, Onivyde, Oxaliplatin, Trans-l-diaminocyclohexanoxalatoplatin
Ludwig-Maximilians - University of Munich
Metastatic Pancreatic Cancer
06/22
06/23
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Recruiting
2
196
Europe
Aflibercept + mLV5FU2, mFOLFOX7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi
Colorectal Cancer
09/22
09/22
AIO-KRK-0116, NCT04034459: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

Checkmark [VIRTUAL] Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
Active, not recruiting
2
109
Europe
Bevacizumab, Irinotecan, Folinic acid, Oxaliplatin, 5-FU, Cetuximab
Ludwig-Maximilians - University of Munich
Metastatic Colorectal Cancer
11/22
12/23
NCT04034173: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Not yet recruiting
2
120
Europe
Panitumumab, Irinotecan, Folinic acid, 5-FU
Ludwig-Maximilians - University of Munich, Amgen, ClinAssess GmbH
Treatment Related Cancer
08/24
08/26
C-PRECISE-01, NCT04495621: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Checkmark [VIRTUAL] MEN1611 in combination with cetuximab: Targeting PIK3CA mutations in RAS-wild-type patient-derived colorectal cancer xenografts
Recruiting
1/2
42
Europe, US
MEN1611, Cetuximab
Menarini Group
Metastatic Colorectal Cancer
07/23
07/23
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25
NCT04852250: Centralized Tumour Board and Secondary Intervention Rate in mCRC

Not yet recruiting
N/A
130
NA
Virtual centralized multidisciplinary tumour board
Ludwig-Maximilians - University of Munich, Charité Universitätsmedizin, Department of Hematology, Oncology and Tumor Immunology
Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication, Secondary Intervention
03/23
03/25

Download Options